PR Newswire Clinical TrialsOriginal article
MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
DA-1726Positive
AI Analysis
Summary
MetaVia announced preclinical tissue distribution findings for DA-1726 demonstrating highest exposure in adipose tissue and prolonged retention, supporting a once-weekly dosing regimen for waist circumference reduction.
Outcome Details
Preclinical tissue distribution study showing highest exposure in adipose tissue and prolonged retention supporting once-weekly dosing
Importance:4/10
Sentiment:
0.60
preclinicalmechanistic studytissue distributionobesityonce-weekly dosing
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 9, 2026 12:00 PM